|

Zirconium Zr 89 Girentuximab Clinical Trials

1 actively recruiting trial across 1 location

Also known as: 89Zr-DFO-TFP-girentuximab, 89Zr-TLX250, 89Zr-girentuximab, Zirconium Zr 89 cG250, Zirconium Zr 89-TLX250

Pipeline

Phase 2: 1

Top Sponsors

  • Jonsson Comprehensive Cancer Center1

Indications

  • Sarcomatoid Renal Cell Carcinoma1
  • Stage II Renal Cell Cancer1
  • Stage IV Renal Cell Cancer1
  • Stage III Renal Cell Cancer1
  • Clear Cell Renal Cell Carcinoma1

Los Angeles, California1 trial

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.